Margo Heath-Chiozzi compensation by year
Celldex Therapeutics Summary Compensation Table · all 8 fiscal years held| Component | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Salary | $370,000 | $377,500 | $393,558 | $409,274 | $424,406 | $440,259 | $461,338 | $483,900 |
| Bonus | $107,000 | $107,000 | $149,000 | $210,000 | $183,286 | $217,500 | $228,034 | $225,450 |
| Stock awards | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Option awards | $119,922 | $89,689 | $668,842 | $1,358,481 | $1,312,773 | $2,269,752 | $2,160,372 | $1,100,875 |
| Non-equity incentive | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| All other | $5,832 | $6,017 | $6,203 | $6,232 | $6,433 | $9,455 | $10,080 | $10,134 |
| Total | $602,754 | $580,206 | $1,217,603 | $1,983,987 | $1,926,898 | $2,936,966 | $2,859,824 | $1,820,359 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Celldex Therapeutics, Inc. DEF 14A filed April 29, 2026, accession 0001104659-26-050884, and prior-year filings.
How this page was built: the Celldex Therapeutics, Inc. filed document, accession 0001104659-26-050884. Every figure is read from that document and cited to the page and table it appears in. Filed April 29, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| Option | 51,250 | — | $36.43 |
| Option | 9,625 | — | $22.48 |
| Option | 30,000 | — | $36.87 |
| Option | 82,000 | — | $19.53 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Celldex Therapeutics, Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
1 Form 4 line since the FY2025 proxy (filed April 29, 2026)current to 2026-11-10 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-06-25 | Grant or award derivative | — | 95,000 | $0.00 | 95,000 |
The 1 most recent of 1 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Celldex Therapeutics’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Anthony Marucci | President, Chief Executive Officer and Director | $5,366,709 |
| Tibor Keler | Executive Vice President and Chief Scientific Officer | $2,115,717 |
| Elizabeth Crowley | Senior Vice President, Chief Product Development Officer | $1,885,209 |
| Sam Martin | Senior Vice President, Chief Financial Officer and Secretary | $1,827,112 |
| Margo Heath-Chiozzi · this page | Senior Vice President, Regulatory Affairs | $1,820,359 |
Board service
Celldex Therapeutics board · FY2023How this board is paid
Company policy: Celldex Therapeutics pays directors a $43,200 cash retainer. As stated in Celldex Therapeutics's FY2023 proxy.
Margo Heath-Chiozzi's compensation dossier, Celldex Therapeutics
You have read Margo Heath-Chiozzi's totals and holdings. The dossier adds each equity grant Celldex Therapeutics disclosed for Margo Heath-Chiozzi and Celldex Therapeutics's own disclosed peer group, where the company discloses them, with every row in a PDF and a CSV cited to its filing.
See an example →The full Celldex Therapeutics compensation record
free company briefThis page is one person within Celldex Therapeutics's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Celldex Therapeutics proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Celldex Therapeutics's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Celldex Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.